CSL Ltd. receives Investment Bank Analyst Rating Update
S&P 500 posts all-time high, helped by a tech rally after US home building data soared NASDAQ notches 34th record this year Treasuries extend rally, dollar rebounds ahead of...
The United States represents about half of the world market cap—the value of shares of all companies globally. While that may seem like a giant piece of the pie, international...
Asian markets are clearly unwilling to rally past the recent highs they set last Friday ahead of the Fed and Bank of Japan (BoJ) meetings. Volumes were down dramatically across the...
CSL Limited (CSL) is an Australia-based biotechnology company. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.
|Average||229.38 (-25.73% Downside)|
|No. of Analysts||18|
|Moving Averages||Sell||Sell||Sell||Buy||Strong Buy|
|Technical Indicators||Buy||Strong Sell||Sell||Strong Buy||Strong Buy|
|Summary||Neutral||Strong Sell||Sell||Strong Buy||Strong Buy|